A case of leptomeningeal carcinomatosis due to a poorly differentiated malignancy is presented. Immunohistochemistry was used to characterize it as a squamous cell carcinoma. Squamous cell carcinomas rarely invade the meninges. There are few well-founded guidelines for managing patients with this condition. Prognosis is generally poor. A literature review of this entity is provided.A 64-year-old African American man presented to the Otolaryngology Clinic with a 1-month history of a left neck mass. The patient had a history of alcoholic liver cirrhosis with a transjugular intrahepatic portosystemic shunt (TIPS) procedure. He was a tobacco user and had chronic obstructive pulmonary disease. A 1 cm, nontender supraclavicular node was observed. A magnetic resonance imaging (MRI) scan of the neck revealed adenopathy in levels II-V and a mass in the posterior aspect of the left parotid gland, invading both superficial and deep lobes. Fine needle aspiration (FNA) of the mass revealed poorly differentiated carcinoma which was focally positive for pancytokeratin (AE1/AE3) and negative for mucin, CK20 and CK7. Endoscopy revealed no visible lesions in the upper aerodigestive tract or esophagus. An excisional biopsy of the parotid mass revealed metastatic poorly differentiated squamous cell carcinoma that was positive for CK5/6 and P63; and negative for AE1/AE3, CK7, CK20, TTF1, CK8/18, S100, HMB45, MART1, CD45, and CD3. Flow cytometry revealed polyclonal B cells. A computerized tomographic (CT) scan of the chest revealed mediastinal and bilateral axillary adenopathy. A fusion positron emission tomographic (PET) scan/CT scan revealed activity in the neck, mediastinum, and axillae but no other areas of concern. An FNA of a right axillary lymph node revealed poorly differentiated squamous cell carcinoma with an immunohistochemical (IHC) staining pattern identical to that of the neck biopsy. The patient was started on chemotherapy consisting of weekly carboplatin (AUC = 2) and weekly paclitaxel (50 mg/m 2 ). He experienced an immediate hypersensitivity reaction to the first dose of paclitaxel and received gemcitabine 1,000 mg/m 2 every other week in its place thereafter. One week after the first cycle of chemotherapy, the patient was noted to be mildly confused and inappropriate. Some improvement resulted from a decrease in narcotic doses, administered for pain.Prior to his third planned cycle of chemotherapy, he presented to the emergency room for headaches, nausea, vomiting, and photophobia. He was found to be confused and disoriented with tangential speech. He was hemodynamically stable and afebrile. Neurological examination revealed ataxia, but there were no cranial nerve, sensory, or motor deficits. Laboratory values revealed a hematocrit of